ROIV Roivant Sciences Ltd.
Stock · NasdaqGS · United Kingdom · Healthcare · BMG762791017
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Roivant Sciences Ltd., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
38.88 USD
+6.17%
52-week range
19.79 – 42.50
Dividend yield—
Market cap28.1B
NowoTrade score
0 Grade A
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:14. Information, not advice.
Results
Next results
09 Nov 2026
in 2 days · 08:00 · estimate -0.30
Last results
-0.34 vs -0.36 estimated
06 Aug 2026 · Beat +4.9%
Beat the estimate
8 of 12
4 missed · 0 in line · 4 beats in a row
Average surprise
+4.9%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 09 Nov 2026 08:00 | -0.30 | — | — | Upcoming |
| 06 Aug 2026 07:00 | -0.36 | -0.34 | +4.9% | Beat |
| 20 May 2026 07:00 | -0.35 | -0.32 | +9.3% | Beat |
| 06 Feb 2026 07:00 | -0.31 | -0.24 | +23.0% | Beat |
| 10 Nov 2025 07:00 | -0.30 | -0.28 | +9.3% | Beat |
| 11 Aug 2025 07:00 | -0.23 | -0.25 | -8.7% | Miss |
| 29 May 2025 07:00 | -0.16 | -0.22 | -33.7% | Miss |
| 10 Feb 2025 07:00 | -0.24 | -0.20 | +17.2% | Beat |
| 12 Nov 2024 07:00 | -0.24 | -0.30 | -23.8% | Miss |
| 08 Aug 2024 07:00 | -0.24 | -0.18 | +25.7% | Beat |
| 30 May 2024 07:00 | -0.29 | -0.23 | +20.1% | Beat |
| 13 Feb 2024 07:00 | -0.27 | -0.21 | +22.3% | Beat |
| 13 Nov 2023 07:00 | -0.27 | -0.29 | -7.1% | Miss |
| 14 Aug 2023 07:00 | -0.28 | -0.28 | -0.7% | In line |
| 28 Jun 2023 07:00 | -0.32 | -0.26 | +21.1% | Beat |
| 13 Feb 2023 07:00 | -0.32 | -0.42 | -30.3% | Miss |
| 14 Nov 2022 08:00 | -0.34 | -0.32 | +3.8% | Beat |
| 15 Aug 2022 07:00 | -0.28 | -0.30 | -6.9% | Miss |
| 28 Jun 2022 06:00 | -0.30 | -0.27 | +10.2% | Beat |
| 14 Feb 2022 07:00 | -0.24 | -0.41 | -71.3% | Miss |
| 15 Nov 2021 07:00 | -0.36 | -0.32 | +11.9% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2026 | 8.3M | -71.6% | -299.8M | -3,629.2% | -0.54 | -125.0% | -758.6M |
| 2025 | 29.1M | -11.2% | -172M | -592.0% | -0.24 | -104.6% | -844.1M |
| 2024 | 32.7M | +3.8% | 4.3B | 13,294.2% | 5.23 | +468.3% | -766.7M |
| 2023 | 31.5M | — | -1B | -3,200.2% | -1.42 | — | -856.1M |
| 2022 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 10 Jun 2024 – 14 Jun 2024 | 10.33 | 10.93 | 10.25 | 10.69 | +2.10% | 18,859,200 | |
| 03 Jun 2024 – 07 Jun 2024 | 10.40 | 11.00 | 10.32 | 10.47 | +1.06% | 22,089,700 | |
| 28 May 2024 – 31 May 2024 | 11.03 | 11.19 | 10.20 | 10.36 | -5.65% | 33,760,200 | |
| 20 May 2024 – 24 May 2024 | 11.23 | 11.49 | 10.86 | 10.98 | -2.23% | 20,072,900 | |
| 13 May 2024 – 17 May 2024 | 11.11 | 11.65 | 10.91 | 11.23 | +0.90% | 14,818,400 | |
| 06 May 2024 – 10 May 2024 | 11.46 | 11.64 | 10.99 | 11.13 | -2.28% | 18,820,200 | |
| 29 Apr 2024 – 03 May 2024 | 11.00 | 11.50 | 10.89 | 11.39 | +3.26% | 22,360,500 | |
| 22 Apr 2024 – 26 Apr 2024 | 10.52 | 11.11 | 10.36 | 11.03 | +5.45% | 19,969,500 | |
| 15 Apr 2024 – 19 Apr 2024 | 10.98 | 11.05 | 10.27 | 10.46 | -4.39% | 21,901,500 | |
| 08 Apr 2024 – 12 Apr 2024 | 11.80 | 11.80 | 10.83 | 10.94 | -6.81% | 25,279,800 | |
| 01 Apr 2024 – 05 Apr 2024 | 10.52 | 11.78 | 10.15 | 11.74 | +11.39% | 68,203,700 | |
| 25 Mar 2024 – 28 Mar 2024 | 10.16 | 11.19 | 9.93 | 10.54 | +3.84% | 104,072,400 | |
| 18 Mar 2024 – 22 Mar 2024 | 10.15 | 10.48 | 9.76 | 10.15 | +0.10% | 24,004,700 | |
| 11 Mar 2024 – 15 Mar 2024 | 10.61 | 10.78 | 10.02 | 10.14 | -5.06% | 30,891,200 | |
| 04 Mar 2024 – 08 Mar 2024 | 11.88 | 12.00 | 10.62 | 10.68 | -9.26% | 27,788,900 | |
| 26 Feb 2024 – 01 Mar 2024 | 11.59 | 11.89 | 11.33 | 11.77 | +1.47% | 22,991,400 | |
| 20 Feb 2024 – 23 Feb 2024 | 11.65 | 11.73 | 11.28 | 11.60 | +0.09% | 16,529,300 | |
| 12 Feb 2024 – 16 Feb 2024 | 10.79 | 11.68 | 10.54 | 11.59 | +7.22% | 30,331,100 | |
| 05 Feb 2024 – 09 Feb 2024 | 9.77 | 11.12 | 9.69 | 10.81 | +9.30% | 23,657,600 | |
| 29 Jan 2024 – 02 Feb 2024 | 10.33 | 10.43 | 9.82 | 9.89 | -4.63% | 49,805,000 | |
| 22 Jan 2024 – 26 Jan 2024 | 10.39 | 10.65 | 10.19 | 10.37 | +0.19% | 19,702,400 | |
| 16 Jan 2024 – 19 Jan 2024 | 11.08 | 11.19 | 10.25 | 10.35 | -6.42% | 17,196,200 | |
| 08 Jan 2024 – 12 Jan 2024 | 11.10 | 11.71 | 10.84 | 11.06 | -1.86% | 22,172,800 | |
| 02 Jan 2024 – 05 Jan 2024 | 11.22 | 11.56 | 10.73 | 11.27 | +0.36% | 20,688,800 | |
| 26 Dec 2023 – 29 Dec 2023 | 11.00 | 11.78 | 10.98 | 11.23 | +3.12% | 22,262,600 |
Page 6 of 11
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value (opens in a new tab) Simply Wall St. · 05 Nov 2026 06:13
- Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials (opens in a new tab) TIKR · 23 Oct 2026 18:25
- Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results (opens in a new tab) MarketBeat · 21 Oct 2026 16:04
- Roivant Sciences stock surges on positive uveitis trial data (opens in a new tab) Investing.com · 21 Oct 2026 14:09
- Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run (opens in a new tab) Simply Wall St. · 19 Oct 2026 01:20
- IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class (opens in a new tab) Stocktwits · 08 Oct 2026 18:33
- Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months (opens in a new tab) MarketBeat · 28 Sep 2026 09:02
- Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging? (opens in a new tab) Insider Monkey · 24 Sep 2026 18:02
- Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss (opens in a new tab) InvestorsHub · 23 Sep 2026 13:12
- Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test (opens in a new tab) Insider Monkey · 22 Sep 2026 11:27
- What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data? (opens in a new tab) Simply Wall St. · 18 Sep 2026 12:15
- Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story (opens in a new tab) Insider Monkey · 13 Sep 2026 10:45
- Podcast: key readouts from ESC and ERS (opens in a new tab) Pharmaceutical Technology · 10 Sep 2026 12:55
- Company News for Sep 9, 2026 (opens in a new tab) Zacks · 09 Sep 2026 12:15
- Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? (opens in a new tab) Stocktwits · 09 Sep 2026 04:00
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 36.62 USD
- Market cap
- 28.1B
- Exchange
- NasdaqGS
- Country
- United Kingdom
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 0.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
- Revenue has fallen two years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -27.93× | Weak | 14.98× |
| Price / book | 6.64× | Weak | 3.94× |
| Price / sales | 3,728.61× | Weak | 3.37× |
| EV / EBITDA | -17.42× | Weak | 12.96× |
| Free cash flow yield | -4% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 59.2% |
| Operating margin | -25,408.1% | Weak | 7.4% |
| Net margin | 0% | Weak | 3.4% |
| Return on equity | -8.5% | Weak | 5.7% |
| Return on assets | -16.3% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | -36% | Weak | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.02× | Good | 0.46× |
| Current ratio | 16.72× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow ROIV and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.